DE10137174A1 - Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität - Google Patents

Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität

Info

Publication number
DE10137174A1
DE10137174A1 DE10137174A DE10137174A DE10137174A1 DE 10137174 A1 DE10137174 A1 DE 10137174A1 DE 10137174 A DE10137174 A DE 10137174A DE 10137174 A DE10137174 A DE 10137174A DE 10137174 A1 DE10137174 A1 DE 10137174A1
Authority
DE
Germany
Prior art keywords
modification
leads
causing
cell population
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10137174A
Other languages
English (en)
Inventor
Juergen Engel
Manfred Peukert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Priority to DE10137174A priority Critical patent/DE10137174A1/de
Priority to PCT/EP2002/008459 priority patent/WO2003011314A2/en
Priority to MXPA04000870A priority patent/MXPA04000870A/es
Priority to NZ531263A priority patent/NZ531263A/en
Priority to IL15928502A priority patent/IL159285A0/xx
Priority to AT02767276T priority patent/ATE315400T1/de
Priority to PL02364492A priority patent/PL364492A1/xx
Priority to CNA028136993A priority patent/CN1525865A/zh
Priority to EP02767276A priority patent/EP1414481B1/de
Priority to BR0211498-4A priority patent/BR0211498A/pt
Priority to DE60208701T priority patent/DE60208701T2/de
Priority to CA002452524A priority patent/CA2452524A1/en
Priority to HU0401634A priority patent/HUP0401634A2/hu
Priority to KR10-2004-7001327A priority patent/KR20040028957A/ko
Priority to JP2003516544A priority patent/JP2005500348A/ja
Priority to RU2004106545/15A priority patent/RU2004106545A/ru
Priority to ARP020102902A priority patent/AR034954A1/es
Publication of DE10137174A1 publication Critical patent/DE10137174A1/de
Priority to ZA200309889A priority patent/ZA200309889B/en
Priority to NO20040350A priority patent/NO20040350L/no
Priority to HR20040186A priority patent/HRP20040186B1/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung bezieht sich auf eine Verwendung von LHRH-Antagonisten bei gleichzeitiger kontrollierter Senkung des Sexualhormonspiegels. DOLLAR A Durch Verwendung von LHRH-Antagonisten zur Senkung des Sexualhormonspiegels wird eine Modifikation der T-Zellen-Population erreicht. DOLLAR A Mittels Steuerung der Dosis oberhalb eines Kastration bewirkenden Spiegels wird eine angestrebte Wirkung auf das Immunsystem erreicht.

Description

  • In einem Patent von R. L. Boyd (WO 200062657, AU 200037977) behauptet der Autor, daß die Unterbrechung der Sexualsteroid-Signalübertragung durch Verabreichung eines LHRH-Agonisten bei Probanden mit einer geschwächten oder abnormalen T-Zellen-Population zu einer Modifikation der T-Zellen-Population führt. Diese Behandlung hat dann die unerwünschte Nebenwirkung, daß der Proband kastriert wird, der Autor behauptet jedoch, daß diese Kastration bei Abbruch der Behandlung reversibel ist.
  • Diese Nebenwirkung ist äußerst unerwünscht, da er zu einem Verlust bzw. einer Verringerung der Libido, des Geschlechtsdrangs und der sexuellen Potenz führt. Bei Männern und bei Frauen vor der Menopause würde die Behandlung auch zu den typischen Symptomen führen, die bei der Erniedrigung des Sexualhormonspiegels unter den Kastration bewirkenden Spiegel auftreten, z. B. Wallungen, und Frauen würden zusätzlich Gefahr laufen, Knochenmineralien zu verlieren, was möglicherweise die Behandlungsdauer einschränkt.
  • Diese unerwünschten Wirkungen könnten dadurch eingeschränkt werden, daß man einen LHRH-Antagonisten in solch einer Dosis verwendet, die nicht zu Kastration führt, jedoch noch die erwünschte Wirkung auf das Immunsystem ausübt.

Claims (7)

1. Verwendung eines peptidartigen oder nichtpeptidartigen LHRH-Antagonisten in geeigneten Dosen, die die Sexualhormonspiegel in gewissem Ausmaß senken, jedoch nicht unterhalb den Kastration bewirkenden Spiegel.
2. Verwendung eines LHRH-Antagonisten in geeigneten Dosen zur Senkung der Sexualhormonspiegel, was zu einer Modifikation der T-Zellen-Population führt.
3. Verwendung eines LHRH-Antagonisten in geeigneten Dosen zur Senkung der Sexualhormonspiegel, was zu einer Modifikation der T-Zellen-Population führt, und zwar bei einem Patienten, der an einer Krankheit leidet, die auf solch eine Modifikation positiv anspricht.
4. Verwendung eines LHRH-Antagonisten in geeigneten Dosen zur Senkung der Sexualhormonspiegel, was zu einer Modifikation der T-Zellen-Population führt, und zwar bei einem Patienten, der an einer HIV- Infektion, an Krebs oder an einer Autoimmunkrankheit leidet.
5. Verwendung eines LHRH-Antagonisten in geeigneten Dosen zur Senkung der Sexualhormonspiegel, was zu einer Modifikation der T-Zellen-Population führt, was zu einer verbesserten Immunreaktion auf ein Antigen führt.
6. Verwendung eines LHRH-Antagonisten in geeigneten Dosen zur Senkung der Sexualhormonspiegel, was zu einer Modifikation der T-Zellen-Population führt, was zu einer verringerten Host-versus-Graft- Reaktion führt.
7. Substanzen, die als LHRH-Antagonisten in der vorliegenden Erfindung verwendet werden können, sind zum Beispiel Cetrorelix, Teverelix, Antide oder Abarelix.
DE10137174A 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität Withdrawn DE10137174A1 (de)

Priority Applications (20)

Application Number Priority Date Filing Date Title
DE10137174A DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
BR0211498-4A BR0211498A (pt) 2001-07-31 2002-07-30 Uso de antagonistas de lhrh em doses que não causam castração, para a melhora de imunidade mediada por células t
HU0401634A HUP0401634A2 (hu) 2001-07-31 2002-07-30 LHRH-antagonisták használata kasztrációt nem okozó dózisokban a T-sejtes immunitás javítására és gyógyszerkészítmények előállítására
NZ531263A NZ531263A (en) 2001-07-31 2002-07-30 Use of cetrorelix to induce an enhanced or decreased immune response without lowering sex hormones to levels below castration level
IL15928502A IL159285A0 (en) 2001-07-31 2002-07-30 Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity
AT02767276T ATE315400T1 (de) 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
PL02364492A PL364492A1 (en) 2001-07-31 2002-07-30 Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity
CNA028136993A CN1525865A (zh) 2001-07-31 2002-07-30 Lhrh-拮抗剂改善t细胞介导的免疫反应的应用
EP02767276A EP1414481B1 (de) 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
PCT/EP2002/008459 WO2003011314A2 (en) 2001-07-31 2002-07-30 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
DE60208701T DE60208701T2 (de) 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
CA002452524A CA2452524A1 (en) 2001-07-31 2002-07-30 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
MXPA04000870A MXPA04000870A (es) 2001-07-31 2002-07-30 Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t.
KR10-2004-7001327A KR20040028957A (ko) 2001-07-31 2002-07-30 Ｔ-세포 매개된 면역 개선용 ｌｈｒｈ-길항제의 용도
JP2003516544A JP2005500348A (ja) 2001-07-31 2002-07-30 Ｔ細胞介在免疫を向上させる際の、去勢状態を誘発しない量でのｌｈｒｈ−拮抗剤の使用
RU2004106545/15A RU2004106545A (ru) 2001-07-31 2002-07-30 Применение антагонистов lhrh для модулирования t-клеточно-опосредованного иммунитета (варианты)
ARP020102902A AR034954A1 (es) 2001-07-31 2002-07-31 Utilizacion de lhrh-antagonistas en dosis que no producen la castracion, para la mejora de la inmunidad mediada por las celulas t
ZA200309889A ZA200309889B (en) 2001-07-31 2003-12-22 Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity.
NO20040350A NO20040350L (no) 2001-07-31 2004-01-26 Anvendelse av LHRH-antagonister i doser som ikke medfører kastrering, for forbedring av T-cellemediert immunitet.
HR20040186A HRP20040186B1 (en) 2001-07-31 2004-02-25 Use of lhrh-antagonists for the improvement of t-cell mediated immunity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10137174A DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität

Publications (1)

Publication Number Publication Date
DE10137174A1 true DE10137174A1 (de) 2003-02-13

Family

ID=7693650

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10137174A Withdrawn DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
DE60208701T Expired - Fee Related DE60208701T2 (de) 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60208701T Expired - Fee Related DE60208701T2 (de) 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom

Country Status (19)

Country Link
EP (1) EP1414481B1 (de)
JP (1) JP2005500348A (de)
KR (1) KR20040028957A (de)
CN (1) CN1525865A (de)
AR (1) AR034954A1 (de)
AT (1) ATE315400T1 (de)
BR (1) BR0211498A (de)
CA (1) CA2452524A1 (de)
DE (2) DE10137174A1 (de)
HR (1) HRP20040186B1 (de)
HU (1) HUP0401634A2 (de)
IL (1) IL159285A0 (de)
MX (1) MXPA04000870A (de)
NO (1) NO20040350L (de)
NZ (1) NZ531263A (de)
PL (1) PL364492A1 (de)
RU (1) RU2004106545A (de)
WO (1) WO2003011314A2 (de)
ZA (1) ZA200309889B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP1891964A1 (de) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Anwendung von Anfangsdosen von LHRH-Analogen und Erhaltungsdosen von LHRH-Antagonisten zur Behandlung von hormonabhängigen Krebsarten und entsprechende Kits
JP2010538989A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｈｂｖ感染等の治療における治療剤としてのｎｆ−カッパーｂインヒビターｓｎ５０の使用、及び必要に応じたアンギオテンシンｉｉｉの使用
WO2009033725A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
EP2095818A1 (de) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen
EP2379099A1 (de) * 2009-01-22 2011-10-26 Maatschap Interne Geneeskunde Rijnstate Verfahren zur prophylaxe oder behandlung von hitzewallungen
WO2016030334A2 (en) 2014-08-26 2016-03-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CN107007814B (zh) * 2016-11-04 2020-03-17 中国科学院昆明动物研究所 西曲瑞克在制备治疗艾滋病的药物中的应用
CN108066763A (zh) * 2017-12-21 2018-05-25 陈敏 Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067123A1 (en) * 1989-09-25 1991-03-26 Esther M. Sternberg Evaluative means for detecting inflammatory reactivity and for predicting response to stress
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
WO1996003138A1 (en) * 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
AU3361695A (en) * 1994-08-10 1996-03-07 Dezso Gaal Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof
AU4459196A (en) * 1995-01-23 1996-08-14 Takeda Chemical Industries Ltd. Sustained-release preparation and use
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
EP1032397A1 (de) * 1997-11-24 2000-09-06 University Of Florida Research Foundation, Inc. Testosterone inhibitoren und verwendung zum neuronalschutz
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
WO2001078780A1 (fr) * 2000-04-13 2001-10-25 Takeda Chemical Industries, Ltd. Agents preventifs/remedes pour la maladie d'alzheimer
CA2462046A1 (en) * 2000-10-13 2002-04-18 Monash University Improvement of graft acceptance through manipulation of thymic regeneration
RU2319501C2 (ru) * 2001-04-30 2008-03-20 Центарис Гмбх Способ лечения болезни альцгеймера
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence

Also Published As

Publication number Publication date
HUP0401634A2 (hu) 2004-12-28
MXPA04000870A (es) 2004-06-03
ZA200309889B (en) 2004-02-19
CN1525865A (zh) 2004-09-01
PL364492A1 (en) 2004-12-13
EP1414481B1 (de) 2006-01-11
IL159285A0 (en) 2004-06-01
JP2005500348A (ja) 2005-01-06
AR034954A1 (es) 2004-03-24
WO2003011314A2 (en) 2003-02-13
EP1414481A2 (de) 2004-05-06
DE60208701D1 (de) 2006-04-06
CA2452524A1 (en) 2003-02-13
WO2003011314A3 (en) 2003-10-16
NO20040350L (no) 2004-01-26
RU2004106545A (ru) 2005-04-10
KR20040028957A (ko) 2004-04-03
DE60208701T2 (de) 2006-08-10
HRP20040186B1 (en) 2007-05-31
ATE315400T1 (de) 2006-02-15
BR0211498A (pt) 2004-08-17
NZ531263A (en) 2005-05-27
HRP20040186A2 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
Krulich et al. The effects of acute stress on the secretion of LH, FSH, prolactin and GH in the normal male rat, with comments on their statistical evaluation
Neill et al. Luteinizing hormone releasing hormone (LHRH) in pituitary stalk blood of rhesus monkeys: relationship to level of LH release
Cagampang et al. Involvement of ovarian steroids and endogenous opioids in the fasting-induced suppression of pulsatile LH release in ovariectomized rats
Matsubayashi et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland
ZELEZNIK et al. Ovarian responses in macaques to pulsatile infusion of follicle-stimulating hormone (FSH) and luteinizing hormone: increased sensitivity of the maturing follicle to FSH
Mason et al. Induction of ovulation with pulsatile luteinising hormone releasing hormone.
KAMBERI et al. Effect of anterior pituitary perfusion and intraventricular injection of catecholamines on FSH release
Ben-Rafael et al. Differences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation
Clarke et al. Pituitary Receptors for Gonadotropin-Releasing Hormone in Relation to Changes in Pituitary and Plasma Gonadotropins in Ovariectom ized Hypothalamo/Pituitary-Disconnected EWES. II. A Marked Rise in Receptor Number during the Acute Feedback Effects of Estradiol
Cetel et al. The dynamics of gonadotropin inhibition in women induced by an antagonistic analog of gonadotropin-releasing hormone
D’Occhio et al. Characteristics of luteinizing hormone (LH) and testosterone secretion, pituitary responses to LH-releasing hormone (LHRH), and reproductive function in young bulls receiving the LHRH agonist deslorelin: effect of castration on LH responses to LHRH
DE10137174A1 (de) Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
Bellows et al. Dose-response relationships in synchronized beef heifers treated with follicle stimulating hormone
Vandevoort et al. Comparison of different regimens of human gonadotropins for superovulation of rhesus monkeys: ovulatory response and subsequent luteal function
BADGER et al. Hypothalamic-pituitary function in adult rats treated neonatally with monosodium glutamate
DE69831241T2 (de) Gonadotropin freisetzendes Hormon Antagonist
DE60010452T2 (de) Programmierte ovarielle stimulationsbehandlungprotokoll unter verwendung von oralen kontrazeptiva
Watanabe et al. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women
Brzuska et al. Artificial spawning of carp Cyprinus carpio L.: differences between the effects on reproduction in females of Israeli strain Dor‐70 and its cross‐breed treated with carp pituitary and Ovopel
Depalo et al. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer
Germain et al. Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight-recovered anorexia nervosa patients
Mutayoba et al. Effects of Trypanosoma congolense infection in rams on the pulsatile secretion of LH and testosterone and responses to injection of GnRH
Del Gadillo et al. Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study
Shi et al. Serous cysts are a benign component of the cyclic ovary in the guinea pig with an incidence dependent upon inhibin bioactivity
Farquhar et al. Deslorelin acetate (Ovuplant) therapy in cycling mares: effect of implant removal on FSH secretion and ovarian function

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: ZENTARIS GMBH, 60314 FRANKFURT, DE

8130 Withdrawal
8127 New person/name/address of the applicant

Owner name: AETERNA ZENTARIS GMBH, 60314 FRANKFURT, DE